Monoclonal Antibody

The monoclonal antibody sotrovimab is no longer authorized by the FDA to treat COVID-19 in certain U.S. regions with high frequency of the omicron BA.2 subvariant.

The FDA has revised its emergency use authorization for the monoclonal antibody cocktail Evusheld, doubling its initial dosing for COVID-19 prevention in light of data suggesting it may be less active against certain omicron subvariants.

WEST PALM BEACH, Florida — Input of baseline characteristics into deep learning machines can reveal subgroups of patients who respond to disease-modifying therapies for primary progressive MS, per a presentation at the ACTRIMS Forum.

A 500 mg intramuscular injection of sotrovimab was noninferior to an IV infusion of the investigational monoclonal antibody for the treatment of mild to moderate COVID-19 in a phase 3 trial, investigators reported.

Bentracimab (PhaseBio) for reversal of ticagrelor (Brilinta, AstraZeneca) in patients with uncontrolled major or life-threatening bleeding or undergoing an urgent invasive procedure.

The FDA authorized the emergency use of bebtelovimab, a monoclonal antibody that retains activity against the omicron variant, for the treatment of COVID-19, according to a press release.

As the COVID-19 pandemic has moved from beta to delta to omicron, often with remarkable speed and unpredictable epidemiology, the efficacy of therapeutic approaches has risen and fallen accordingly.

The FDA halted the use of two monoclonal antibody treatments for COVID-19 because they are not effective against the omicron variant of SARS-CoV-2, which now accounts for almost all U.S. cases.

The Healio and Endocrine Today editors have compiled the top news about diabetes from 2021.

National Comprehensive Cancer Network has issued updated guidance on COVID-19 vaccination and pre-exposure prophylaxis for patients with cancer.